Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAVENCLAD vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
FDA: Treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate metabolite. It is also phosphorylated by other nucleoside kinases. The elimination half-life is approximately 1 day. Renal excretion of unchanged drug accounts for about 18% of the dose.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
20% bound to plasma proteins, primarily albumin. No significant binding to alpha1-acid glycoprotein.
82–88% bound to plasma proteins (primarily albumin).
Apparent volume of distribution is approximately 4.3 L/kg (range 1-9 L/kg). This large Vd indicates extensive extravascular distribution, including penetration into cells and tissues, particularly lymphocytes. Clinical meaning: High tissue distribution correlates with intracellular loading in target immune cells.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral bioavailability of cladribine from MAVENCLAD is approximately 40% (range 30-50%). It is converted to active triphosphate intracellularly, so prodrug absorption is similar. Food reduces absorption by ~20% but does not affect clinical effect.
Oral: 65–80% (median 73%)
Contraindicated in patients with estimated GFR <30 m L/min/1.73 m2 due to potential accumulation and increased risk of adverse reactions. No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2).
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Not approved for use in pediatric patients less than 18 years of age. Safety and efficacy have not been established.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended based on age alone. However, renal function should be assessed and dosing should be based on e GFR as in younger adults. Experience in patients over 60 years of age is limited.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
WARNING: MALIGNANCIES. Cladribine can increase the risk of malignancies (including cases of cancer-related deaths). Because of this risk, MAVENCLAD should be used in patients who have had an inadequate response to, or are unable to tolerate, other drugs indicated for the treatment of MS.
None
Risk of malignancies: including treatment-emergent malignancies (e.g., cancers of the lung, gastrointestinal tract, skin, breast, and others).,Hematologic toxicity: severe bone marrow suppression (thrombocytopenia, anemia, neutropenia); monitor CBC counts before and during treatment.,Infections: increased risk of serious infections, including opportunistic infections (e.g., tuberculosis, herpes zoster, progressive multifocal leukoencephalopathy); screen for latent infections before initiation.,Hepatic injury: cases of drug-induced liver injury; monitor liver enzymes.,Fetal risk: can cause fetal harm; advise females of reproductive potential to use effective contraception during and for 6 months after the last dose.,Vaccinations: avoid live vaccines during and after treatment.,Impaired renal function: use with caution; cladribine pharmacokinetics may be altered.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Current malignancy.,Patients with HIV infection.,Active chronic infections (e.g., tuberculosis, hepatitis).,Hypersensitivity to cladribine or any component of the formulation.,Women who are pregnant or breastfeeding.,Concomitant use with other immunosuppressive or myelosuppressive therapies (except corticosteroids for acute exacerbations).
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No significant food interactions reported. Avoid grapefruit and grapefruit juice as they may alter drug metabolism.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of fetal harm, including teratogenicity and embryolethality. In humans, no adequate controlled studies exist; therefore, use in all trimesters is contraindicated. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
It is unknown whether cladribine is excreted in human breast milk. However, due to the potential for serious adverse reactions in nursing infants and the drug's long half-life, breastfeeding is not recommended during treatment and for at least 10 days after the last dose. M/P ratio is not available.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
MAVENCLAD is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as the drug is not to be administered to pregnant women.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Mavenclad (cladribine) is an oral purine antimetabolite approved for relapsing multiple sclerosis. It is given as two short courses per year for two years. Monitor for lymphopenia, infections, and malignancies. Contraindicated in patients with active infections or current malignancy. Do not use in patients with HIV or hepatitis B/C. Live vaccines contraindicated during and after treatment. Pregnancy category D; effective contraception required. Monitor liver enzymes and bilirubin. Consider PCP and VZV prophylaxis if lymphopenia severe. MRI monitoring for PML is recommended.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Mavenclad is taken in two treatment courses per year, each consisting of 4 or 5 days of tablets, for 2 years.,You need regular blood tests to monitor your white blood cell count, liver function, and for infections.,Avoid live vaccines during treatment and for at least 1 year after the last dose.,Use effective contraception during treatment and for at least 6 months after the last dose.,Report any signs of infection (fever, chills, cough), unusual bleeding, or easy bruising immediately.,Do not take Mavenclad if you have an active infection, cancer, or HIV/hepatitis B or C.,Avoid grapefruit products during treatment.,Store tablets at room temperature away from moisture.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAVENCLAD vs AGRYLIN, answered by our medical review team.
MAVENCLAD is a Antineoplastic Agent that works by Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAVENCLAD and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAVENCLAD is: 3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAVENCLAD and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAVENCLAD is classified as Category C. MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of . AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.